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The potentially detrimental effects of cancer and related treatments on cognitive function-
ing are emerging as a key focus of cancer survivorship research. Many patients with central
nervous system (CNS) or non-CNS tumours develop cognitive problems during the course
of their disease that can result in diminished functional independence. We review the state
of knowledge on the cognitive functioning of patients with primary and secondary brain
tumours at diagnosis, during and after therapy, and discuss current initiatives to diminish
cognitive decline in these patients. Similarly, attention is paid to the cognitive sequelae of
cancer and cancer therapies in patients without CNS disease. Disease and treatment effects
on cognition are discussed, as well as current insights into the neural substrates and the
mechanisms underlying cognitive dysfunction in these patients. In addition, rehabilitation
strategies for patients with non-CNS disease confronted with cognitive dysfunction are
described. Special attention is given to knowledge gaps in the area of cancer and cognition,
in CNS and non-CNS diseases. Finally, we point to the important role for cooperative groups
to include cognitive endpoints in clinical trials in order to accelerate our understanding and
treatment of cognitive dysfunction related to cancer and cancer therapies.
 2014 European Organisation for Research and Treatment of Cancer. Published by Elsevier
Limited. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).nlaan 121,
30 E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 2 9 –4 01. Introduction grade I and II) tumours typically present with epileptic sei-Compared to classical oncological outcome measures such as
time to progression and survival, the importance of cognitive
functioning in cancer patients has only recently been recogni-
sed. In patients with tumours either inside or outside the cen-
tral nervous system (CNS), cognitive functioning is a critical
outcome measure because cognitive dysfunction can have a
large impact on the daily life of patients [1,2]. Even mild cog-
nitive difficulties can have functional and psychiatric conse-
quences – especially when persistent and left untreated.
Deficits in specific cognitive domains such as memory, atten-
tion, executive function and processing speed may pro-
foundly affect quality of life. For example, cognitive
impairment negatively affects professional reintegration,
interpersonal relationships and leisure activities. In addition,
fear of future cognitive decline may also negatively affect
quality of life.
Long-term cancer survivors are steadily increasing and
many patients may develop cognitive dysfunction that can
result in diminished functional independence. In this paper
that focuses on cognitive functioning in cancer patients, we
summarise the knowledge on the incidence and determi-
nants of cognitive dysfunction in both patients with CNS
and non-CNS cancers, the neuropsychological pattern and
structural brain changes associated with various anti-cancer
treatments, risk factors for developing neurotoxicity, as well
as current treatment options to prevent or diminish adverse
effects on cognition. Important knowledge gaps are discussed
and future directions are presented. Specific attention is paid
to the key role research cooperative groups hold to advance
our understanding of cancer and cancer therapy-associated
cognitive dysfunction – an understanding that forms the basis
of preserving and enhancing cognitive function.
2. Cognition in primary and metastatic brain
tumour patients
2.1. Primary brain tumours
The most commonly occurring primary brain tumours are gli-
omas (originating from the supportive cells of the CNS) and
meningiomas (originating from the dural coverings of the
brain), with annual incidence rates of approximately 7 and 9
per 100,000 per year respectively [3]. The incidence is low in
absolute numbers when compared to the major cancer
groups, but considerable when their impact on the health
care system and the informal caregivers is concerned. Treat-
ment usually consists of a combination of surgery, irradiation
and chemotherapy, the choice depending on histological sub-
type and malignancy grade according to the World Health
Organisation (WHO) classification [4,5]. The median survival
ranges from approximately 14 months for glioblastoma
(GBM, WHO grade IV) patients to more than 10 years for
low-grade oligodendroglioma (WHO grade II) patients, and
even longer for WHO grade I meningioma patients that have
a 5-year survival of approximately 95% and are considered
to be ‘benign’ tumours [5]. Patients with low-grade (WHOzures, whereas many patients with higher tumour grades
(WHO grade III and IV) present with progressive neurological
deficits [4].
2.2. Metastatic brain tumours
Approximately 20–40% of patients with a systemic malig-
nancy will develop brain metastases during the course of
their illness. Lung cancer, melanoma, renal cell carcinoma
and breast cancer are the most common primary tumours
that metastasise to the brain. Melanoma has the highest rate
relative to other primary tumours, with 75% of patients with
disseminated disease developing brain metastases. With best
supportive care and depending on performance status, extent
of extracranial disease, and age, the median survival time is
approximately 1–2 months. Radiotherapy increases the med-
ian survival to 3–5 months, and further survival benefit might
be achieved in specific subgroups through combinations of
surgery, stereotactic radiotherapy, whole brain radiotherapy
(WBRT) and systemic therapies [6]. The initial symptoms
patients present with are similar to patients with primary
brain tumours, but cognitive dysfunction, including memory
problems and mood or personality changes, is already pres-
ent in 90 percent of patients with brain metastases [7].
2.3. Cognitive functioning at presentation
Even at first presentation, many, if not all, patients with pri-
mary and metastatic brain tumours have cognitive deficits.
Reijneveld et al. showed that patients with presumed low-
grade glioma (WHO grade II) already suffered from cognitive
deficits compared to matched healthy controls [8]. The same
is true for patients with high-grade glioma prior to surgery
[9] or prior to the initiation of radiotherapy [10]. Contrary to
what was presumed historically, even most patients with sus-
pected WHO grade I meningiomas show subtle cognitive def-
icits [11]. In patients with brain metastases [7], cognitive
dysfunction is more correlated with the volume than with
the number of metastases [12]. In general, cognitive deficits
manifest in accordance with our traditional understanding
of brain behaviour relationships – specifically, greater deficits
in verbally mediated cognitive functions are seen in patients
with left hemisphere tumours compared to patients with
right hemisphere tumours. However, when compared to
patients with stroke, more subtle and diffuse patterns of cog-
nitive deficits are seen in patients with brain tumours [13].
2.4. Cognitive functioning during treatment
Virtually all patients with gliomas and metastatic brain
tumours cannot be cured from their disease. Therefore, palli-
ation of symptoms and sustained or improved quality of life
are considered as equally important treatment goals as pro-
longed survival and postponed tumour progression. Evalua-
tion of treatment outcome in brain tumour patients should
therefore focus beyond survival endpoints, and should also
aim at avoiding adverse treatment effects on the normal brain
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Research in this area during recent years has provided several
important insights. As stated, numerous studies have demon-
strated that the tumour itself can have a profound adverse
impact on cognition. Resecting the tumour in a symptomatic
patient may result in both deterioration and improvement of
cognitive functioning.
Tumour progression during or after state of the art first-
line treatment for GBM is frequently accompanied by rapid
cognitive decline [15], and cognitive deterioration has predic-
tive power regarding survival [14–16]. While most GBM
patients with stable disease after first-line treatment show
stable cognitive functioning, a substantial minority evidences
signs of cognitive decline [14–18].
Seizures and treatment with older antiepileptic drugs
(AEDs) in particular might have a negative impact on cogni-
tive function of primary brain tumour patients [17], while
newer AEDsmight have no or even a beneficial impact on cog-
nition [18,19].
The critical importance of assessing patient-oriented out-
comes such as a cognitive function (arguably a cardinal symp-
tom of a brain tumour) in brain tumour clinical trials is
exemplified by the results of a recent large randomised trial
examining the benefit of bevacizumab in patients with newly
diagnosed GBM. In RTOG 0825 [20] as well as Avaglio [20,21],
patients randomised to bevacizumab lived no longer than
those randomised to placebo. Patients in the bevacizumab
arm in both trials experienced a longer progression free
survival. However, in RTOG 0825 patients with newly
diagnosed GBM that received bevacizumab were found to
demonstrate greater objectively tested and subjectively
reported cognitive decline during the progression free period
[20]. The evidence is mixed in terms of the impact
bevacizumab has on patient’s subjectively reported health
related quality of life [20,21].
Several important observations were noted in a large trial
of patients receiving WBRT for brain metastases with or with-
out motexafin gadolinium, in which cognitive function was
prospectively assessed at baseline andmultiple intervals until
death [7]. Over 90% of patients had evidence of cognitive
impairment at baseline. The extent of impairment at baseline
was correlated with lesion volume prior to treatment, and a
higher baseline cognitive function was associated with a
longer overall survival. In this trial, cognition, quality of life
and functional independence were serially monitored at the
same time points after therapy. Cognitive function was
strongly associated with functional independence and QOL
at baseline. Cognitive decline occurred sooner and was pre-
dictive of later reductions in QOL and activities of daily living
[22].
2.5. Long-term cognitive functioning
With improved long-term survival for subgroups of primary
brain tumour patients [23,24], the quality of that survival
becomes even more essential. If treatments that result in
effective tumour control are associated with cognitive impair-
ments and worse health-related quality of life in the long run,
longer survival may be less meaningful for patients. Klein
et al. demonstrated that low-grade glioma patients withstable disease who had undergone radiotherapy had poorer
cognitive function on an average 6 years following diagnosis
and initial treatment compared to patients who had not
undergone irradiation. Additionally, both groups had poorer
cognitive performance than healthy controls and patients
with haematological malignancies [25]. Patients who had
undergone irradiation fractions >2 Gy were found to be at par-
ticular risk. Continued follow-up for another 6 years demon-
strated that irradiated patients had further cognitive
decline, while patients who had not undergone irradiation
remained stable [26]. In another study, the impact of epilepsy
and antiepileptic drug treatment on cognitive functioning and
quality of life in these patients was examined. Eighty-six per-
cent of patients had epilepsy and 50% of those using AEDs
were actually seizure-free. The increase in epilepsy burden
(based on seizure frequency and AED use) associatedwith sig-
nificant reductions in all cognitive domains except for atten-
tion and memory functioning, was primarily attributed to the
use of AEDs, whereas the decline in health-related Quality of
Life (HRQOL) was ascribed to the lack of complete seizure
control [17]. In a cohort of 27 progression-free anaplastic
(WHO grade III) oligodendroglioma patients, status post irra-
diation with or without procarbazine, lomustine, vincristine
(PCV) chemotherapy within the past twelve years, 30% were
severely cognitively impaired [27]. These data suggest that gli-
oma patients who respond favourably to first-line treatment
might actually be at risk for long-term radiotherapy-related
cognitive decline, although more information is needed to
draw more definite conclusions. Moreover, no data exist
regarding the long-term effects of chemotherapy on cognitive
performance of brain tumour patients, stressing the need for
long-term cognitive follow-up in brain tumour patients
undergoing (experimental) first-line treatment [28].
2.6. Prevention and rehabilitation
Optimal safe treatment of the tumour is essential to aide in
the preservation and possible restoration of cognitive func-
tioning in brain tumour patients. Optimal treatment implies
application of state-of-the-art resective surgical and RT tech-
niques [26], avoiding excessively high fraction doses [29].
Damage to neural stem cells found in the subventricular zone
and dentate gyrus in the hippocampus may play a role in pre-
venting recovery from radiation induced memory deficits [29–
31]. Gondi et al. [30] found that biologically equivalent doses
of 7.3 Gy to 40% or more of the bilateral hippocampi corre-
sponded with a 50% chance of developing memory decline
within 18 months of completing radiation therapy. Inten-
sity-modulated radiation therapy has been suggested as a
way to spare neural stem cells when treating brain tumours
[32]. Preliminary results from a recent phase II trial [33] found
that administering whole brain radiation therapy with hippo-
campal avoidance when treating patients with brain metasta-
ses was associated with a substantial and statistically
significant reduction in memory dysfunction four months
after therapy. Previously, pharmacological intervention stud-
ies have not convincingly demonstrated effectiveness. The
beneficial effects reported in some studies of psychostimu-
lants [34] could at least in part be attributed to a placebo-
effect, and the only proper placebo-controlled study did not
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symptom management [35]. Recently, a randomised placebo
controlled trial of memantine reported delayed time to cogni-
tive decline in patients with brain metastases that received
whole brain radiation therapy [36]. Cognitive rehabilitation
programs for the improvement of attention, memory and
executive function, as well as comprehensive programs
which combine neuropsychological and pharmacological
treatment modalities may also be effective in patients with
brain tumours [37].
2.7. Knowledge gaps and future opportunities
During the last decade, the neuro-oncological research com-
munity has become more aware of the importance of cogni-
tive function as an outcome in experimental studies for
primary brain tumour patients. Cognitive testing, utilising
standardised tests with published normative data, moderate
to high test–retest reliability, brief administration time and
suitability for monitoring changes over time are becoming
standard practice in most EORTC Brain Tumour Group clinical
trials. Despite a growing understanding of the cognitive
impact of CNS tumours and their treatment, we still have
many knowledge gaps that need to be addressed in the com-
ing generation of clinical trials, for which cognitive testing
should be mandatory practice.
Small case series reports have identified differences in the
cognitive sequelae from low- and high-grade brain tumours.
However, we have a limited understanding of why these dif-
ferences are present and how this may relate to therapies that
maximise tumour control while minimising patient morbidi-
ties such as cognitive dysfunction. For example, do low-grade
tumours exclusively offer an opportunity for the brain to reor-
ganise, providing impetus for delayed or staged resections in
patients at risk for surgically induced cognitive dysfunction?
Are patients with IDH1-mutant tumours also good candidates
for delayed or staged interventions? Can we identify who is at
risk for surgically induced cognitive decline? Is it possible to
predict who is most likely to experience functional re-organi-
sation? Are there active approaches (i.e. cognitive training)
that may facilitate reorganisation and/or restoration? Simi-
larly, what patient factors (e.g. genetics, cognitive reserve)
serve as protective factors that allow subsets of patients to
tolerate therapies better than other patients? If we were able
to identify comprehensive clinical–molecular phenotypes
that predicted response and toxicity we would be better
equipped to offer the most effective and safest therapy to
our brain tumour patients.
While radiation therapy is a critical component of treat-
ment for many brain tumour patients, and is delivered in rel-
atively homogeneous doses at this time, it is unclear if the
dose is optimal and safest for all patients. For example, some
patients may be able to tolerate dose-escalated radiation
without adverse effects, while others may receive equal
tumour control and a better toxicity profile from a lower dose
schedule. Different forms (e.g. photons versus protons) and
delivery methods (e.g. intensity modulated, radiosurgery,
whole brain with or without critical structure avoidance), as
well as the use of radiosensitisers and neuroprotectants, have
offered some promise in preventing or reducing cognitivedecline associated with radiotherapy. However, we are only
at the beginning stages of understanding and evaluating
these issues.
Exciting results [23,24] have recently emerged demonstrat-
ing substantial gains in overall survival for patients with 1p/
19q codeleted and IDH1 mutant anaplastic oligodendroglial
tumours who received PVC chemotherapy and radiation
[38,39].
However, routine formal cognitive testing was not per-
formed in these studies. Cognitive assessment carried out
with a small cohort of long-term survivors of the EORTC study
showed that 30% were severely cognitively impaired [27]. The
number of patients, however, was too small to determine the
impact of the addition of PCV chemotherapy over RT alone on
long-term cognitive functioning. The neuro-oncology com-
munity remains torn about the use of PCV as it is believed
to be more toxic than temozolomide. Unfortunately, we have
a very limited understanding of the cognitive effects of PCV
and perhaps an equally limited understanding of the effects
of temozolomide, which has been the standard of care che-
motherapy for the largest group of primary brain tumour
patients studied in clinical trials for almost the last decade.
With the arrival of many new targeted agents and immuno-
therapies it is unclear if these will have greater or less cogni-
tive effects.
Clearly there is a great need and opportunity to more fully
understand the cognitive risks and benefits of these therapies
that are being specifically directed at the brain, which may
have ‘off target’ adverse effects on normal brain tissues,
resulting in cognitive decline. Furthermore, we have relatively
limited insight into the risk factors and time course of cogni-
tive dysfunction in patients treated for CNS cancer, as not all
patients develop this neurotoxicity and not everyone experi-
ences these symptoms at the same time points. Linking cog-
nitive outcomes with the correlative biological and imaging
science within clinical trials will help enhance our under-
standing of the mechanisms accounting for cognitive decline
and resilience, and inform future therapeutic trials designed
to preserve or enhance cognitive function in this patient
population.3. Cognition in patients without central
nervous system disease
In contrast to treatment for brain tumour patients, therapies
for non-CNS disease are much more often given with the
expectation of cure. Nowadays more than one in three people
will be diagnosed with some form of cancer during their life-
time. For many people, treatments other than local therapies
will be required for long-term survival, making the impact of
such therapies on the patient’s well-being very important.
During the past years, a steadily accumulating body of evi-
dence has indicated that a subgroup of cancer patients with
non-central nervous system disease is vulnerable to treat-
ment-related cognitive impairment. With respect to chemo-
therapy, human and preclinical studies into the occurrence
and determinants of cognitive impairment in non-CNS cancer
patients have demonstrated that many commonly used cyto-
toxic agents can drive neurobiological processes contributing
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been predominantly studied in breast cancer patients under-
going adjuvant chemotherapy, several clinical studies suggest
that other cancer populations for whom chemotherapy is a
treatment strategy (e.g. testicular and colon cancer) may
experience similar cognitive symptoms. In addition, patients
with haematologic malignancies might be particularly vul-
nerable to cognitive side effects, as treatments like CNS-pro-
phylaxis, biological response modifiers and hematopoietic
stem cell transplantation (HSCT) increase the neurotoxic bur-
den. Cognitive effects of endocrine treatment for breast and
prostate cancer may also occur, given the important role of
hormones in the brain. While the research regarding hor-
monal therapies and cognitive functioning is inconsistent,
recent reviews suggest potential negative impact on specific
cognitive domains. Even with newer classes of compounds
that target dysregulated cellular signalling pathways driving
malignant cells, recent studies raise concerns about neuro-
logic complications.
3.1. Cognitive functioning at presentation and following
chemotherapy
The majority of prospective neuropsychological studies in
breast cancer patients show that a substantial subgroup of
patients have cognitive decline after chemotherapy, with inci-
dence rates generally varying between 20% and 60% [40–44].
Patients show changes from pre- to post chemotherapy with
regard to learning andmemory, speed of information process-
ing and executive functioning [45–48] (see for a detailed
reviewWefel [49]). A recent study in testicular cancer patients
found that compared with a surveillance group, patients trea-
ted with mostly BEP chemotherapy had higher rates of cogni-
tive decline at 12 months after treatment, with overall
cognitive decline of 0%, 52% and 67% in the surveillance,
low exposure and higher exposure chemotherapy groups
respectively [50]. Similarly, a first prospective study in colon
cancer patients receiving FOLFOX4 indicated adverse effects
on verbal memory in a subgroup of patients [51]. In HSCT
patients, objective cognitive decline has been found in nearly
half of the patients at 1–3 months [52,53] and 16% of patients
at 1 year post-HSCT [54]. Moreover, twice as many allogeneic
HSCT patients compared to case-matched controls showed at
least mild cognitive impairment at a 5-year follow-up [55]. In
addition to the cognitive domains known to be affected in for
example breast cancer patients, impairment in manual dex-
terity is common in HSCT recipients.
Cross-sectional studies of long-term breast cancer survi-
vors indicate the presence of cognitive differences between
chemotherapy-treated patients and non-cancer controls up
to 20 years post-therapy, suggesting the persistence of cogni-
tive impairment over the years [56,57]. Preclinical and child-
hood cancer survivor studies show that therapies including
chemotherapy may accelerate aging [58], [59,60]. In what
way cancer and cancer treatment in adult patients and
patients of older age affect the trajectories of cognitive
decline, is as yet undetermined but deserves intensified
attention.
Intriguingly, studies that included baseline testing have
found that cognitive impairment may already be present invarious cancer populations before the start of treatment
[61]. This phenomenon is putatively linked to inflammatory
responses triggering neurotoxic cytokines, common risk fac-
tors for the development of cancer and cognitive decline, sur-
gery-related factors or psychological distress/symptoms of
fatigue and stressing the importance of pre-therapy
assessment.
3.1.1. Risk factors for cognitive decline
In terms of disease-related and patient-related risk factors for
cognitive decline, much research is still needed. There is
some indication of a dose–response relationship. One study
observed that more patients exhibited cognitive decline fol-
lowing high-dose chemotherapy compared to conventional
dose chemotherapy [62], while another study showed a linear
decline in cognitive performance after consecutive cycles of
chemotherapy [63]. Nonetheless, direct comparisons of the
toxicity profiles of common chemotherapeutic regimens are
lacking. The finding that a subgroup of breast cancer patients
experiencing persistent post-treatment cognitive decline has
led to the examination of patient-related risk factors for cog-
nitive change. However, until now, patient-related risk factors
such as age, cognitive reserve, distress, presence of co-morbid
conditions or other established risk factors, have not been
identified as strong contributors to the impact of chemother-
apy on cognitive function [44]. Given the small sample sizes in
nearly all existing studies, exploration of sociodemographic
or clinical predictors of cognitive decline is likely underpow-
ered. This also holds true for genetic factors examined as
potential risk factors for cognitive decline. The relationship
between genetic polymorphisms, for example APOE and
COMT, with cognition has not been consistent across the lim-
ited number of studies exploring this relationship [64]. Other
studies on blood-based biomarkers that may mediate chemo-
therapy-associated cognitive decline suggest that the role of
circulating proinflammatory cytokines in post-chemotherapy
cognitive decline is still controversial and requires further
evaluation [65].
3.1.2. Neural substrates and underlying mechanisms
In terms of neural substrates and underlying mechanisms,
studies have documented white matter pathology in patients
within a few months and after 10 years post-chemotherapy,
for both high-dose and standard-dose regimens [66–69]. Stud-
ies using voxel-based morphometry have reported volume
reductions of white and grey matter at one year [70] and
20 years after completion of chemotherapy [68]. Imaging
studies indicate that chemotherapy seems to particularly
affect the integrity [71] of the white matter with several stud-
ies demonstrating a link between the abnormal microstruc-
tural properties of specific white matter regions and
cognitive impairments seen in patients treated with chemo-
therapeutic agents [72].
Advances at the basic science level are providing a detailed
view of the pathogenesis of chemotherapy-related cognitive
decline which may foster the development of better tools
for early intervention and treatment. It is known that neural
progenitor cells and mature post-mitotic oligodendrocytes
are the most vulnerable cell populations to various chemo-
therapeutic agents [73,74]. Long-term cognitive decline in
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decreased proliferation of neural progenitor cells, impaired
hippocampal neurogenesis and damage to oligodendroglial
cells and white matter tracts [75]. As many different chemo-
therapeutic agents seem to have similar effects on the CNS,
studies are also exploring common indirect mechanisms of
neurotoxicity, such as pro-oxidative effects, toxic neurotrans-
mitters/monoamine release, disruption of blood vessel den-
sity and supply and inflammation [76].
3.2. Cognitive functioning and endocrine therapy
A treatment-related risk factor for cognitive decline in breast
cancer patients is the use of endocrine therapy with selective
oestrogen receptor modulators (SERMs) and/or aromatase
inhibitors (AIs). Evidence derived from basic and clinical
research indicates that oestradiol administered within a spe-
cific window of time can stimulate neuroplasticity and
improve cognitive performance [77–79]. SERMs and AIs also
target brain areas involved in the regulation of cognition
and behaviour and may contribute to cognitive changes.
Blocking oestradiol synthesis with AIs deprives the brain from
modulation via oestradiol theoretically resulting in decreased
neuroplasticity and impaired cognitive functioning. Surpris-
ingly, studies in breast cancer patients seem to generally indi-
cate that AIs are less consistently adversely influencing
cognitive functioning compared to SERMs [80,81]. SERMs bind
to oestrogen receptors, but whether a given SERM will func-
tion as an ER agonist or antagonist is target tissue-dependent
and varies among individual SERMs. Basic research is rather
conclusive about the neuroprotective properties of SERMs in
the absence of circulating oestradiol, but clinical studies dem-
onstrate that treatment with SERMs has a detrimental effect
on cognitive functioning, particularly in older breast cancer
patients [82]. In view of the already widespread and poten-
tially even more frequent long-term use of endocrine treat-
ment in the future, more research is needed. Also, research
addressing the interaction between chemotherapy and endo-
crine therapy is particularly sparse, and the majority of stud-
ies have been too small to adequately investigate this
interaction. Absence of oestrogen neuroprotective action in
the brain, either in the natural, surgical or chemotherapy-
induced postmenopausal brain, potentially increases vulner-
ability to neural damage by chemotherapy.
Preclinical models used to assess the impact of androgen
blockade on the brain have revealed adverse effects that are
limited to specific areas, particularly the hippocampus, with
deficits related to spatial abilities and encoding new memo-
ries [83,84]. A recent review of the influence of ADT on cogni-
tive functioning of prostate cancer patients concluded that
most studies do not provide substantial evidence of cognitive
impairment with ADT. At the same time, the authors identi-
fied major methodological limitations of current research,
including the omission of cognitive domains that are theoret-
ically at the highest risk of being affected by ADT [85]. Based
on the best controlled studies, a potential negative impact of
ADTon spatial memory and verbal memory is suggested, and
these studies stress the need for continued investigation of
the impact of ADT on cognition. Given the large number of
patients on ADT, cognitive side effects are important toconsider, especially since more than half of new prostate can-
cers occur at an age where patients are already at increased
risk for cognitive decline.
3.3. Cognitive functioning and targeted agents
The development of targeted agents focused on molecular or
vascular pathways has transformed cancer treatment,
improving efficacy. These innovative therapies are applied
in the treatment of many cancers (i.e. sarcoma, colon, breast,
renal and lung cancer) [86], usually for prolonged and
repeated exposure, either alone or in association with tradi-
tional anti-cancer agents such as chemotherapy and endo-
crine therapy. Side-effects induced by these new treatments
usually differ from those observed with chemotherapy, are
class-specific, and some remain poorly documented. Their
impact on inflammation and angiogenesis may specifically
contribute to the onset of cognitive dysfunctions and/or
increase of cognitive impairment induced by chemotherapy
[87]. Based on their pharmacological properties, anti-angio-
genic agents have been subjected to the most comprehensive
investigation, indicating that patients treated with anti-
angiogenic tyrosine kinase inhibitors report frequent severe
fatigue and concentration difficulties, yielding a negative
impact on quality of life [88]. Some clinical case series have
been published reporting reversible cognitive disorders such
as confusion, memory loss and word finding difficulties with
the use of sunitinib. Additionally, rare but potentially severe
posterior encephalopathy syndromes may occur with the
monoclonal antibody bevacizumab, even in normotensive
patients [89,90]. In a recent longitudinal study of renal cancer
patients treated with anti-angiogenic tyrosine kinase inhibi-
tors, a decline of objective cognitive functions from baseline
was observed in 31% of cases (mainly executive functions
and episodic memory), suggesting a direct neurotoxic effect
of treatment [91]. However, the biological mechanisms impli-
cated in these cognitive disorders remain unclear. Recent
work suggests that vascular endothelial growth factor (VEGF)
has a central role and that VEGF inhibitors might affect cogni-
tive functioning through action on neurogenesis, cerebral
blood flow and modulation of long-term potentiation [92,93].
Immune dysregulation and cytokine release are among the
other postulated mechanisms [87].
The literature is limited regarding cognitive effects of other
targeted agents. Some of those as mTOR inhibitors (rapamy-
cin, everolimus) might actually provide protection from cog-
nitive impairment. Indeed, preclinical work on everolimus
has shown a potential for slowing the aging process [94]
and decreasing the risk of Alzheimer disease. Proposedmech-
anisms of action include progressive desensitisation of nor-
mal brain insulin and IGF-1 responses, the aberrant
proteostasis of Ab and tau and the synaptic loss seen in Alz-
heimer disease. This collateral action might prove very useful
for the growing elderly cancer population and is an area of
research with potential to improve the tolerance of these
new agents in the future [95].
Immunomodulators indicated in haematologic disease
may also have potential negative impact on cognition when
used in association with chemotherapy. Lenalidomide, a
derivative of thalidomidewith anti-tumour, anti-angiogenesis
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nitive disorders (notably episodic memory impairments) in
some patients. The putative mechanism by which lenalido-
mide impacts cognition is not well known, though it is proba-
bly facilitated by specific risk factors, such as previous
chemotherapy, prior mild cognitive impairment, age and the
presence of cerebrovascular lesions. The anti-angiogenic
effect might also prohibit neurogenesis in hippocampal struc-
tures and lenalidomide can cross the blood–brain barrier into
the central nervous system, having a direct cerebral effect [96].
Since many other new agents in development target different
specific pathways, assessing their potential impact on cogni-
tive function will be a real challenge for the near future. These
assessments will need to take into account symptom clusters
including emotional factors, as mood alterations have been
documented with agents such as the BKM120 oral pan PI3-
kinase inhibitor [97] .
3.4. The relation between cognitive symptoms and other
cancer-related symptoms
Cancer patients provide convincing testimony of distressing
cognitive symptoms after cancer treatment, placing a burden
on daily functioning. Cognitive dysfunction in itself alters
mental functioning, causes distress, and results in reduced
quality of life. However, cancer patients also suffer from the
presence of multiple, often co-occurring symptoms, and iso-
lated symptoms seldom reflect patients’ clinical situation.
These symptom clusters, if not attended to, could result in a
less comprehensive approach to the management of cogni-
tive problems. Understanding other symptoms in the context
of cognitive dysfunction, such as fatigue, sleep disturbance,
affective vulnerability and mood disorders might help deter-
mine how these symptoms contribute to the occurrence
and persistence of cognitive impairment. Therefore, assess-
ment of such symptoms should be an essential part of the
clinical work-up.
Fatigue represents the most common side effect of cancer
treatment and can persist in a substantial proportion of survi-
vors, affecting physical, psychological and social well-being.
Fatigue is strongly linked with sleep disorders and meno-
pausal symptoms such as hot flashes [98]. These clustered
symptoms have a severe impact on health-related quality of
life. A recent comprehensive study of patients with different
types of cancer, all receiving chemotherapy, revealed a high
prevalence of insomnia symptoms and related syndromes.
In a longitudinal study where almost 40% of patients experi-
enced persistence of an insomnia syndrome, there was a con-
nection with menopausal symptoms and fatigue, acting as
triggers for the development of insomnia [99,100].
Cognitive dysfunction affects several aspects of quality of
life, such as employment, social functioning and indepen-
dence [101]. Although subjective cognitive complaints are at
best weakly associated with tested cognitive function, self-
perceived cognitive problems correlate much more frequently
and stronger with fatigue, anxiety and depression [44,102].
The latter symptoms should be taken into account as they
can affect perception of cognitive performance via attentional
bias in which anxious and depressed people perceive theirfailures as more severe. Co-occurring anxiety and depression
may also have synergistic effects on executive dysfunction, as
shown by studies in which individuals with co-morbid
depressive and anxiety disorders performed worse on some
executive function tasks compared to individuals with
depression or anxiety alone [103]. These findings stress the
importance of systematic assessment of areas other than
cognition. Specifically, early detection and intervention for
mood, fatigue and sleep disturbances hold the possibility of
contributing to the reduction of cognitive problems.
3.5. Rehabilitation
Unraveling the precise mechanisms underlying treatment-
related cognitive side effects is necessary to enable the iden-
tification of novel treatment strategies. Pharmacological
interventions to prevent or intervene against cognitive symp-
toms in non-CNS cancer patients are in the early stage of
development. Some agents are promising, but rigorous test-
ing with appropriate study designs and sufficient sample
sizes necessary to translate and implement these agents in
daily practice are either absent or have generated disappoint-
ing results [104]. For example several studies found positive
effects of Erythropoietin (EPO) on cognitive functioning dur-
ing or shortly after chemotherapy, but randomised controlled
studies at longer follow-up failed to show positive effects of
EPO on cognition. Psychostimulants like methylphenidate
and modafinil have been tested in several studies, but the
effectiveness of methylphenidate to treat cancer therapy
associated cognitive dysfunction is at present not established.
Initial small studies with modafinil are slightly more hopeful,
but larger studies with longer follow-up are needed before
conclusions about the effectiveness can be drawn [105].
Another example of an agent that received attention follow-
ing initial interesting preclinical findings but for which con-
vincing data from phase III studies on the efficacy is
lacking, is donepezil. Multiple behavioural based studies have
proven successful in improving daily life functioning using
intact cognitive abilities and strategies together with psy-
cho-education [106–111]. Interventions like mindfulness-
based stress reduction and exercise interventions are gaining
increasing attention as potential effective interventions for
cancer and cancer-treatment related cognitive effects, and
several large trials are underway which should clarify the
value of these behavioural interventions. Likewise, interven-
tions focusing on mental stimulation, collectively known as
brain training, are frequently accessed by cancer survivors.
Although reviews of the current brain training literature indi-
cate that most programs still fail to display fundamental
transfer, there is hope that the next generation of brain train-
ing programs capitalising on novelty to stimulate plasticity to
the highest extent, will result in robust generalisation of
trained skills [112].
3.6. Knowledge gaps and future opportunities
We have learnt that treatment-related cognitive decline occur
in patients with non-CNS disease. This holds true for patients
receiving chemotherapeutic agents, endocrine agents and
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alone may be associated with lower than expected cognitive
function, an as yet poorly understood finding that at the very
least indicate the importance of a pre-treatment baseline
measure. Most research has been done in the area of chemo-
therapy-related cognitive decline, but despite clear progress,
several fundamental questions still need to be answered.
These questions centre on the actual incidence of cognitive
decline (e.g. how many patients are affected, and for which
proportion of patients does cognitive decline interfere with
daily life activities?) and on the trajectory of cognitive decline
(i.e. does chemotherapy cause acceleration of aging or even
put patients at increased risk for dementia?). And, are there
regimen-specific toxicity profiles, and do these profiles
change or increase in severity when combined with other
treatment strategies, such as endocrine or targeted therapies?
The considerable variation across patients in the presence of
cognitive decline points to specific host factors that may drive
the association between chemotherapy and cognitive decline.
From the literature, relevant clues for these patient-related
risk factors emerge, but these factors are unsatisfactorily clar-
ified. Are patients of higher age and with lower cognitive or
brain reserve more vulnerable, what is the influence of
comorbid conditions, and can we identify genetic influences
that modulate the exposure to cancer and cancer therapies?
The emphasis in the current literature has been on study-
ing the effects of adjuvant chemotherapy for breast cancer,
mainly assessing patients in their midlife. From the preceding
review it is apparent that there is fair body of evidence linking
a much wider spectrum of chemotherapeutic regimens for a
variety of cancers to cognitive decline. In these patient
groups, cognitive functioning should be monitored as well
to understand which therapies are most and least likely to
lead to cognitive decline. Regarding the role of endocrine ther-
apies on cognitive functioning, much less research has been
done, and a very complex body of findings has been reported.
Many studies lack an adequate sample size and use non-opti-
mal selection of neuropsychological tests (i.e. they do not
assess domains expected to be impacted by changes in the
hormonal milieu). From the current literature no reliable con-
clusion can be drawn on the presence, pattern and strength of
cognitive effects of various endocrine therapies for patients
with hormone-sensitive tumours, nor if the brain recovers
from adverse effects after switching to a different class of
agents or upon completion of endocrine treatment. Endocrine
therapies are applied to many cancer patients, with a trend
for even longer periods of administration. There is a high
need to embark on endocrine therapy trials to gain adequate
data regarding the cognitive effects of these therapies and to
guide optimal treatment choices and best duration of
treatment.
Finally, little is known about the cell–biological conse-
quences of many new agents that target different specific sig-
nalling pathways. Assessing their independent impact on
cognitive function as well as their influence when combined
with other cancer treatments will be an important task in
the near future, since there is evidence that similar signalling
mechanisms are also implicated in the biology of neural pro-
genitor cells and maintenance of brain plasticity.4. Assessment of cognitive function: trial
design opportunities
The importance of assessing cognitive functioning in brain
tumour patients has been recognised and cognitive endpoints
are added more frequently by cooperative groups including
the EORTC Brain Tumour Group. The recent trend towards
incorporating cognitive testing into clinical trials also in the
case of patients with non-CNS disease is applauded and wel-
comed. The Response Assessment in Neuro-Oncology (RANO)
working groups [113,114] and the International Cognition and
Cancer Task Force (ICCTF) [49] have proposed a core set of
cognitive tests measuring memory, executive function and
processing speed and these tests are widely adopted by the
EORTC, Radiation Therapy Oncology Group (RTOG) and other
consortia. The tests can be administrated after a short train-
ing and do not need on-site neuropsychological expertise.
The incorporation of such a brief cognitive battery into the
main protocols enables accurate, efficient and unobtrusive
monitoring of different therapies with respect to their poten-
tial cognitive sequelae and determine their relationships with
other symptoms, with sufficient power to permit important
subgroup analyses driven by biological hypotheses.
The inclusion of cognitive endpoints brings both opportu-
nities and challenges, including developing amethodology for
combining or evaluating the cognitive endpoints with the
more traditional survival endpoints. Additionally, it should
be clarified which clinical trials, in what phase, with which
patient population, require or would benefit from inclusion
of cognitive testing. For example, it could be argued that in tri-
als of agents intending to reach the brain, monitoring cogni-
tion should be mandatory at any phase and in any patient
population. Information from phase I and II trials would
inform the development of phase III trials. Alternatively, one
may argue that promising compounds should first pass the
early safety screening phase, and then in the context of com-
parative effectiveness designs (as we have limited historical
cognitive data for most agents) should routinely include cog-
nitive testing. For many neurologic diseases cognition is the
primary outcome. However, in oncology this has rarely been
the case. Are there times when cognitive function is the best
as a primary, secondary or exploratory outcome?
Running parallel to these issues are opportunities to fur-
ther enhance the precision of our cognitive tests. Within the
context of international trials, further improvements can be
achieved by simultaneously collecting healthy control data,
developing mechanisms to minimise missing data that con-
founded some prior trials, and by defining the frequency
and timing of cognitive testing on study (e.g. should testing
occur at fix intervals, every time the patient is restaged,
should testing only be conducted when patients are stable
or up until death?). We can also evaluate which statistical
models are best suited to what study questions regarding cog-
nition in these populations, standardise and validate a defini-
tion of clinical significance apart from statistical significance,
and recognise and manage potential floor and ceiling effects
in these outcome measures. Regardless of how these ques-
tions may be answered eventually, neurocognitive testing is
a cornerstone of adequate care for CNS and non-CNS patients
E J C S U P P L E M E N T S 1 2 ( 2 0 1 4 ) 2 9 –4 0 37facing cognitive decline. Moreover, the development of modi-
fying interventions for cancer and cancer therapy-related
cognitive decline will likely depend on the wide application
of these cognitive diagnostic methods.
Research cooperative groups are best positioned to pro-
gress our knowledge on the cognitive effects of cancer and
cancer therapies and present an excellent and cost-efficient
utilisation of scientific assets to examine and promote cogni-
tive health [115]. By routinely including cognitive endpoints in
combination with other patient-oriented endpoints in clinical
cancer trials, we can closely monitor and ultimately reduce
the total burden of physical andmental morbidity. The EORTC
survivorship initiative takes an important first step by recogn-
ising the need to include such patient-oriented endpoints in
addition to standard efficacy endpoints in a more systematic
way in order to provide better care for our cancer patients and
the growing community of cancer survivors.
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